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Abstract
Systemic Lupus Erythematosus (SLE) pathology has long been associated with an increased Epstein-Barr Virus (EBV)
seropositivity, viremia and cross-reactive serum antibodies specific for both virus and self. It has therefore been postulated
that EBV triggers SLE immunopathology, although the mechanism remains elusive. Here, we investigate whether frequent
peaks of EBV viral load in SLE patients are a consequence of dysfunctional anti-EBV CD8
+ T cell responses. Both inactive and
active SLE patients (n=76 and 42, respectively), have significantly elevated EBV viral loads (P=0.003 and 0.002, respectively)
compared to age- and sex-matched healthy controls (n=29). Interestingly, less EBV-specific CD8
+ T cells are able to secrete
multiple cytokines (IFN-c, TNF-a, IL-2 and MIP-1b) in inactive and active SLE patients compared to controls (P=0.0003 and
0.0084, respectively). Moreover, EBV-specific CD8
+ T cells are also less cytotoxic in SLE patients than in controls (CD107a
expression: P=0.0009, Granzyme B release: P=0.0001). Importantly, cytomegalovirus (CMV)-specific responses were not
found significantly altered in SLE patients. Furthermore, we demonstrate that EBV-specific CD8
+ T cell impairment is a
consequence of their Programmed Death 1 (PD-1) receptor up-regulation, as blocking this pathway reverses the
dysfunctional phenotype. Finally, prospective monitoring of lupus patients revealed that disease flares precede EBV
reactivation. In conclusion, EBV-specific CD8
+ T cell responses in SLE patients are functionally impaired, but EBV reactivation
appears to be an aggravating consequence rather than a cause of SLE immunopathology. We therefore propose that
autoimmune B cell activation during flares drives frequent EBV reactivation, which contributes in a vicious circle to the
perpetuation of immune activation in SLE patients.
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Introduction
Systemic lupus erythematosus (SLE) is a chronic autoimmune
disorder. Common manifestations include inflammation and tissue
damage of skin and joints as well as inner organs, such as brain
and kidneys, in severe cases. The disease can be fatal, but with
recent medical advances, mortality is reduced significantly. The
course of the disease is unpredictable, with peak periods of illness
(active SLE) alternating with periods of remission (inactive SLE).
SLE-related autoimmune symptoms can be triggered by
environmental factors, such as ultraviolet light, drugs and
viruses.[1,2] In this regard, it has been reported that lupus
patients have elevated antibody responses to the gamma-
herpesvirus EBV [3,4] and that this antibody response shows
cross-reactivity to nuclear self antigens.[5,6,7,8] Primary EBV
infection typically occurs during childhood without apparent
clinical symptoms and evolves into a non-symptomatic life-long
virus carrying latency. Rare cases of infection in early adulthood
lead to infectious mononucleosis (IM), which has been linked to
increased risk of Hodgkin’s lymphoma [9] and to the onset of
autoimmune diseases, such as Multiple Sclerosis (MS) [10] and less
documented cases of rheumatoid arthritis (RA) and SLE, as
reviewed by Mu ¨nz et al.[2] Detectable levels of lytic EBV antigen,
BZLF1, were observed more frequently in SLE patients (35%)
than in healthy controls (0%), suggesting recurrent EBV
replication in SLE patients.[11] In line with this observation,
several groups demonstrated that EBV viral load is elevated in
SLE patients,[12,13] and that the number of infected B cells
monitored longitudinally is positively correlated with the SLE
disease activity index (SLEDAI).[11] However, the mechanisms
linking EBV to SLE immunopathology still remain elusive. On the
one hand, EBV-related disorders are often observed as a
consequence of immunodeficiency in hosts, such as bone marrow
transplant patients.[14] On the other hand, it is debated that EBV
transformation can support the survival of self-reactive B cells.[2]
It has furthermore been demonstrated that EBV nuclear antigen 1
(EBNA1) is capable of inducing T [15,16] and B cell responses
[5,6,7,8] cross-reactive to auto-antigens, and thus potentially
induce auto-immunity. Of note, IM patients have cross-reactive
antibody responses to EBNA1 and the common lupus spliceo-
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IM,[17] suggesting a connection between the immunopathology of
EBV-induced IM and SLE.[18]
It was reported in an early study that T cells from SLE patients
are unable to control immunoglobulin production from EBV-
exposed B cells.[19] Subsequently, Kang et al. observed that lupus
patients had elevated frequencies of interferon-c (IFN-c) secreting
EBV-specific CD4
+ T cells, whereas no significant modification
was observed for IFN-c secreting EBV-specific CD8
+ T cells.[12]
Similarly, Berner et al. reported that the frequency of EBV-specific
CD8
+ T cells did not differ between SLE patients and healthy
controls, when analysed using peptide-MHC tetramer probes.
However, the capacity of EBV-specific CD8
+ T cells to secrete
IFN-c seemed reduced in SLE patients compared to healthy
controls.[20] Altogether, whether the defective control of latent
EBV infection in SLE patients is related to a CD8
+ T cell defect
remains controversial.[11,12,13] Furthermore, it is unclear
whether the defect is EBV-specific or global. Finally, the sequence
in which EBV re-activation and disease onset occurs is unresolved.
Here, we assess quantitative and qualitative attributes of EBV-
specific CD8
+ T cells from SLE patients. We show that the
frequencies of IFN-c, tumour necrosis factor-a (TNF-a), interleu-
kin-2 (IL-2) and Macrophage Inflammatory Protein 1b (MIP-1b or
CCL4) secretion by EBV-specific CD8
+ T cells upon antigen
stimulation are diminished in SLE patients compared to healthy
controls. We furthermore demonstrate that EBV-specific T cells
from SLE patients exhibit a marked impairment in their cytotoxic
granule exocytosis process. We finally associate the dysfunctional
T cell phenotype with the up-regulation of the inhibitory receptor
programmed death 1 (PD-1), and strengthen this association by
reversing the dysfunctional T cell phenotype through specific
blockade of the PD-1 signaling pathway. In line with previous
findings, EBV viral load was found to be elevated in SLE patients
compared to healthy controls. Interestingly, longitudinal monitor-
ing revealed that bursts of viral load always occurred in a delayed
manner with respect to disease flare onset.
Results
SLE patients have elevated EBV viral load
To study the impact of EBV infection on SLE immunopathol-
ogy, we established a cohort of SLE patients and age- and sex-
matched healthy controls. Patient characteristics and treatments
are presented in Table 1. We validated that the patients displayed
the EBV associated features identified in literature,[3,4] such as
increased EBV seroprevalance (P=0.006) and augmented anti-
EBV antibody titers (P,0.0001) (Table 1). Furthermore, we
confirm that cell-associated EBV viral load is augmented in EBV
seropositive SLE patients, when compared with EBV seropositive
healthy controls.[12,13] Thus, cell-associated EBV DNA is more
frequently above detection threshold in SLE patients than in
healthy controls (Figure 1). In comparison, CMV was below
detection threshold in the majority of study subjects (Healthy: 0 of
18; SLE: 5 of 93, P=0.59). We then explored whether cell-
associated EBV viral load is linked with disease activity. As shown,
EBV was as frequently detectable in inactive as in active patients
(Figure 1). EBV viral loads were not influenced by any treatment-
related parameters (corticosteroids, hydroxychloroquine and other
immunosuppressors – see Table 1) according to a multivariate
analysis (P=0.40, 0.21 and 0.24, respectively, n=118).
Expansion of EBV-specific CD8
+ T cells counterbalanced
by lymphopenia
In order to address whether increased EBV viral loads in SLE
patients could be due to a T cell functional defect, we compared
phenotypic and functional characteristics of lytic (BMLF1,
BMRF1, BZLF1) and latent (EBNA3A and EBNA3B) EBV-
specific CD8
+ T cell responses between patients with SLE and
healthy controls. Using HLA/peptide tetramers, we quantified
circulating lytic and latent EBV- and CMV pp65-specific CD8
+ T
cells in patients and controls (Figure 2A and Figure S1A in Text
S1). As shown, inactive and active SLE patients have slightly
elevated frequencies of lytic EBV-, and comparable frequencies of
latent EBV- and CMV-specific CD8
+ T cells compared to healthy
controls (Figure 2B and Figure S1B in Text S1). However, the
elevated lytic EBV-specific CD8
+ T cell frequency is counterbal-
anced by a general lymphopenia (Figure S2A in Text S1). Thus,
absolute counts of lytic EBV-specific CD8
+ T cells in SLE patients
are comparable (inactive SLE patients) or even slightly decreased
(active SLE patients) as compared to healthy controls (Figure S2B
in Text S1).
Defective EBV-specific CD8
+ T cell cytokine secretion in
SLE patients
MHC class I tetramer positive EBV- and CMV-specific CD8
+
T cells were then tested for their capacity to secrete IFN-c, TNF-a,
IL-2 and MIP-1b in response to stimulation with EBV and CMV
cognate antigens (Figure 2A). We found that CD8
+ T cells from
inactive and active SLE patients specific for lytic EBV antigens are
functionally impaired in their capacity to secrete IFN-c (P=0.003
and 0.021, respectively), TNF-a (P=0.005 and 0.004, respective-
ly), IL-2 (P=0.004 and 0.0001, respectively) and MIP-1b
(P=0.001 and 0.0001, respectively) compared to T cells from
healthy controls (Figure 2C – upper panel). The impairment is also
observed as a decline in the absolute number of circulating
cytokine-secreting EBV-specific CD8
+ T cells (Figure S2C in Text
S1). Moreover, the proportion of EBV-specific CD8
+ T cells able
to secrete multiple cytokines is reduced in patients compared to
controls (Figure 2D – upper panel). Similarly, we observed that
CD8
+ T cells from SLE patients specific for latent EBV antigens
tend to have reduced capacity to secrete IFN-c (Figures S1A and
Author Summary
Systemic Lupus Erythematosus (SLE) has been associated
with Epstein-Barr Virus (EBV) infection for decades,
however the mechanistic links have remained elusive.
Most human adults are infected by EBV and carry the virus
for life without clinical symptoms. However, for unknown
reasons EBV induces infectious mononucleosis in some
individuals, during which cross-reactive antibodies specific
for both virus and self have been detected. Interestingly,
such cross-reactive antibodies are also frequently found in
SLE patients. Since, EBV seropositivity and viremia are
more frequent in SLE patients than in healthy individuals, it
has been postulated that EBV trigger autoimmunity. Here
we show that SLE patients are indeed less capable of
controlling EBV viremia, since their EBV-specific CD8
+ T
cells have diminished capacity to secrete effector mole-
cules (e.g. cytokines and chemokines) and to kill EBV-
infected targets as a consequence of their Programmed
Death 1 (PD-1) receptor up-regulation. Longitudinal
studies further reveal that disease flares precede EBV
viremia. Thus, contrary to expectations, EBV reactivation
appears to be an aggravating consequence, rather than a
cause, of SLE immunopathology. Our results pave the way
for immunological interventions that restore the host-EBV
balance, which may result in decreased levels of aggra-
vating cross-reactive antibodies and ultimately be benefi-
cial to SLE patients.
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well preserved in inactive and active SLE patients (Figure 2C –
lower panel). Likewise, polyfunctionality of CMV-specific CD8
+ T
cells do not differ significantly between patients and controls
(Figure 2D – lower panel). Importantly, impaired functionality of
EBV-specific CD8
+ T cells is not related to treatments
(corticosteroids, hydroxychloroquine and other immunosupres-
sors) according to a multivariate statistical analysis (All treatment
parameters were non-significant for the prediction of IFN-c-, IL-
2-, MIP-1b- and TNF-a-secretion, n=46).
Figure 1. Cell-associated EBV viral load in SLE patients. qPCR measurements of EBV genomes per 10
6 PBMCs from EBV seropositive healthy
controls (H, n=29), inactive (iSLE, n=76) and active (aSLE, n=42) SLE patients. The absolute number and the frequency of individuals having viral
loads above the detection limit of 25 viral genomes per 10
6 PBMCs (dotted line) are indicated. Group comparisons are performed with Fisher’s exact
test.
doi:10.1371/journal.ppat.1002328.g001
Table 1. Cohort characteristics.
Healthy
controls (n=31)
Inactive SLE
patients (n=76)
Active SLE
patients (n=42) P-value
Female Sex (%) 27 (87%) 71 (93%) 36 (86%) 0.32
Inclusion age (years), Median 33.0 34.3 34.6 0.92
[Range] [19–57] [16–61] [16–58]
SLEDAI, Median N/A 0 8 0.0001
[Range] [0–5] [6–23]
EBV Serology 29 (92%) 76 (100%) 42 (100%) 0.006
A
CMV Serology 18 (58%) 58 (76%) 35 (83%) 0.035
A
Anti-EBV IgG titers
B, Median (RU/ml) 10500 17900 19300 ,0.0001
A
[Range] [2400–25400] [2900–28900] [2800–35400]
Corticosteroid (%) N/A 73% 65% 0.49
Median (mg/day) [Range] 5 [0–55] 7.5 [0–60]
Hydroxychloroquine (%) N/A 89% 87% 0.76
Other immunosuppressors (%) N/A 23% 26% 0.81
N/A: not applicable, RU: Relative Units.
AHealthy controls versus all SLE patients.
BOnly titers from seropositive individuals are included.
doi:10.1371/journal.ppat.1002328.t001
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We then investigated whether EBV-specific CD8
+ T cells
from SLE patients are also less cytotoxic than their healthy
counterparts. We measured the capacity of EBV-specific
CD8
+ T cells to degranulate by monitoring the appearance of
degranulation marker LAMP-1 (CD107a) on the cell surface
(Figures 3A–B) and granzyme B release (Figures 3C–D), prior to
and following stimulation with cognate antigen. Surface exposed
CD107a is inversely correlated with granzyme B release, and thus
a marker of recent history of cytotoxic activity.[21] As shown,
Figure 2. Multiparametric functional assessment of EBV- and CMV-specific CD8
+ T cells in SLE patients. (A) Representative
cytofluorometric detection (left) and functional analysis (right) of CD8
+ T cells specific for one of the lytic EBV antigens tested (BZLF1) in a healthy
control (upper panel) and in an inactive SLE patient (lover panel) post peptide antigen stimulation of PBMC. Lytic EBV and CMV antigen-specific cells
were detected with peptide/MHC tetramer and anti-CD8 antibody (red box) and simultaneously analyzed for intra-cellular IFN-c, TNF-a, IL-2 and MIP-
1b content. Cytokine/chemokine gates were positioned according to control stains of non-stimulated virus-specific T cells. (B) Magnitude and (C)
functionality of EBV- (upper panel) and CMV-specific (lower panel) responses in healthy controls (H, n=26 and 15, respectively), inactive (i, n=19 and
10) and active (a, n=27 and 11) SLE patients. (D) EBV-specific T cells (upper panel) are strikingly less polyfunctional in inactive (iSLE) and active (aSLE)
SLE patients compared to controls (healthy), while polyfunctionality of CMV-specific responses (lower panel) is preserved. Pie representations of virus-
specific CD8
+ T cells represent the fraction of individual cells secreting none (0) or any (1, 2, 3 or 4) of the four cytokines IFN-c, TNF-a, IL-2 and MIP-1b
(color coded as indicated). E.g. the red pie slice indicates the proportion of cells producing four cytokines (IFN-c, TNF-a, IL-2 and MIP-1b). P-values
monitoring differences between healthy donors and SLE patients are calculated using a non-parametric Mann-Whitney test and pie comparison
statistics of the Spice software.
doi:10.1371/journal.ppat.1002328.g002
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+ T cells from SLE patients specific for lytic EBV antigens
carry similar loads of granzyme B (Figure 3D – upper left panel),
but are dramatically less able to degranulate (P=0.0009,
Figure 3B upper panel) and release their cytotoxic content
(P=0.0001, Figure 3D – upper right panel) following stimulation,
compared to EBV-specific CD8
+ T cells from healthy controls. A
Figure 3. Lytic EBV antigen-specific T cells from SLE patients are impaired in their ability to release their cytotoxic granule content.
Representative analysis of (A) CD107a and (C) granzyme B expression in CD8
+ T cells, specific for one of the lytic EBV antigens tested (BZLF1), from
healthy control and SLE patient either ex vivo (upper panel) or following cognate antigen stimulation (lower panel). As shown, EBV-specific CD8
+ T
cells from SLE patients are much less able to mobilize surface CD107a and release their granzyme B content upon cognate antigen stimulation. (B)
Mobilization of CD107a on the surface of EBV- (upper panel) and CMV-specific (lower panel) CD8
+ T cells upon cognate antigen stimulation over
night. (D) Ex vivo analysis of the frequency of granzyme B expression in EBV- and CMV-specific CD8
+ T cells from healthy controls (n=17 and 11,
respectively) and SLE patients (n=14 and 12) (left panel), as well as the frequency of EBV- and CMV- specific CD8
+ T cells positive for granzyme B
capable of releasing their granzyme B upon cognate antigen stimulation (right panel). Healthy controls are compared to SLE patients using a non-
parametric Mann-Whitney test.
doi:10.1371/journal.ppat.1002328.g003
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+ T
cells specific for latent EBV antigens (CD107a, P=0.050)
(Figures S1A and S1C in Text S1). In contrast, CMV-specific
CD8
+ T cells from SLE patients retain their cytotoxic potential
(Figures 3B and 3D lower panels). We conclude from this first set
of experiments that there is an EBV-specific CD8
+ Tc e l l
functional defect in SLE patients, the latter cells being impaired
in their capacity to secrete multiple effector cytokines and in their
cytotoxic granule exocytosis process.
PD-1 is upregulated on EBV-specific CD8
+ T cells from SLE
patients
To investigate the mechanism of EBV-specific CD8
+ Tc e l l
dysfunction, we performed a comparative combinatorial analysis
of markers expressed by SLE versus control CD8
+ T cells. We
measured expression levels of a range of differentiation
(CD45RA, CCR7, CD27, CD57, FoxP3), co-stimulatory/co-
inhibitory (CTLA-4, ICOS, PD-1, CD80, CD86, 41BBL, ICOSL
and PD-L1), activation (HLA-DR, CD69 and CD38) and
proliferation (Ki-67) markers on EBV-specific cells and total
CD8
+ T cells. We found that the balance between central
memory, effector memory and naı ¨ve CD8
+ T cell subsets is not
altered in SLE patients, compared to healthy controls (data not
shown). However, proliferation (Ki-67) and activation (HLA-DR,
CD69 and CD38) markers are significantly up-regulated on total
CD8
+ T cells in active SLE patients and less pronounced in
inactive SLE patients compared to controls (Figures S3A–B in
Text S1). Also EBV-specific T cells show a trend to be more
activated in SLE patients compared to healthy controls (Figure
S3C in Text S1). In addition, we found that whereas inhibitory
receptor CTLA-4 expression is conserved (Figure S4A in Text
S1), PD-1 expression is up-regulated on total CD8
+ T cells
(p=0.005 and 0.008 for inactive and active SLE, respectively)
compared to healthy controls (Figure S4B in Text S1).
Interestingly, polyclonal stimulation of CD8
+ T cells with
Staphylococcal Enterotoxin B (Figure S4C in Text S1), anti-
CD3 and anti-CD28 antibodies (Figure S4D in Text S1) or PMA-
Ionomycin (Figure S4E in Text S1) mounted lower responses in
SLE patients compared to healthy controls. Importantly, EBV-
specific CD8
+ T cells represent one of the T cell subsets
expressing high PD-1 levels in SLE, compared to controls
(Figure 4A; p=0.0004). In contrast, CMV-specific CD8
+ T cells
from SLE patients do not express elevated levels of PD-1
(Figure 4A).
Figure 4. Blockade of PD-1 signalling revigorates EBV-specific T cell responses. Cytofluorometric analysis of PD-1 expression on lytic (black
circles) and latent (red triangles) EBV- (upper panel) as well as CMV-specific (lower panel) CD8
+ T cells. (B) Overall cell growth, (C) virus-specific T cell
expansion and (D) IFN-c secretion by peripheral virus-specific CD8
+ T cells from healthy controls (H) and SLE patients (SLE) stimulated for 10 days with
EBV cognate antigen in the presence (+) or absence (2) of PD-L1 and PD-L2 antagonistic antibodies. Statistical comparisons are performed using (A)
Mann-Whitney and (B–D) Wilcoxon matched pairs test.
doi:10.1371/journal.ppat.1002328.g004
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+ T cells from
SLE patients
Since PD-1 expression has previously been associated with
impaired cellular functionality,[22] we then asked whether
increased PD-1 expression by EBV-specific CD8
+ T cells from
SLE patients could account for their impaired functional capacity.
In HIV-infected patients, it was shown that blockade of the PD-1
inhibitory pathway can restore CD8
+ T cell functionality.[23] We
therefore tested the influence of the PD-1 signaling pathway on
EBV-specific CD8
+ T cells by blocking PD-1 signaling with
antagonistic antibodies specific for PD-1’s two known ligands, PD-
L1 and PD-L2. Blockade of PD-1 signaling during lytic and latent
EBV antigen stimulation substantially boosted general T cell
proliferation (Figure 4B), EBV-specific T cell expansion (Figure 4C)
and IFN-c secretion (Figure 4D) in PBMC cultures from SLE
patients but not from healthy controls. In contrast, blockade of
PD-1 signalling during CMV antigen stimulation neither boosted
general T cell proliferation (Figure 4B) nor CMV-specific T cell
expansion (Figure 4C) or IFN-c secretion (Figure 4D). We
conclude that the PD-1 inhibitory pathway appears to have a
particularly important deleterious impact on lytic and latent EBV-
specific CD8
+ T cell responses in SLE patients.
EBV replication peaks post initiation of SLE disease flare
Although EBV replication was found increased both in active
and inactive patients, we reasoned that only longitudinal studies
would clearly decipher whether EBV viral bursts precede or follow
disease flares. In order to address this issue, SLEDAI and EBV
viral load were longitudinally recorded from initiation of disease
flare to clinical and biological recovery in 6 established SLE
patients (Figure 5A) and 5 healthy controls (Figure 5B). An
increase of EBV viral load was observed in all SLE patients
(Figure 5A). In contrast, EBV remained below detection levels in
the 5 healthy controls monitored during the 8 weeks follow-up
(Figure 5B). Importantly, viral replication peaked 1 week or more
post flare onset in all 6 patients followed longitudinally, EBV being
below detection level in 4 of these patients at time of hospital
admission (Figure 5A). We confirmed in the cross-sectional series
of flaring patients that EBV was below detection levels in 5 out of 7
cases studied at the time of their hospital admission. We conclude
Figure 5. Longitudinal monitoring of EBV replication following SLE flare onset. EBV viral load as genome copies per 10
6 PBMCs (black line)
and synchronous disease activity (gray shading, SLEDAI$6) in (A) 6 SLE patients and (B) 5 healthy controls.
doi:10.1371/journal.ppat.1002328.g005
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clinical symptoms of SLE do not coincide with high EBV viral
load.
Discussion
Alterations in the control of EBV infection in individuals
susceptible to lupus are suspected to promote the development of
autoimmunity through multiple mechanisms, such as cross-
reactive antibody and T cell responses.[24] Here we show that
SLE patients have recurrent bursts of EBV viral load. We
furthermore associate this altered control of EBV infection with a
PD-1 induced impairment of T cell mediated immune surveillance
of EBV.
Virus-specific T cells play a crucial role in the control of EBV
infection, and have already been the focus of previous studies in
human SLE.[12,19] Berner et al. addressed the issue by combining
MHC-peptide tetramer staining with IFN-c ELISPOT analysis.
Based on these tests, it was suggested that EBV-specific T cells
from SLE patients might have impaired IFN-c secreting
capacity.[20] The latter study was however hampered by
limitations in cohort size, and by the fact that function and
frequency of EBV-specific CD8
+ T cells were not monitored
simultaneously at the single cell level.
The present study was designed to concurrently assess the
quality and quantity of EBV-specific CD8
+ T cell responses. This
was achieved by combining the analysis of IFN-c, TNF-a IL-2,
MIP-1b, CD107a and granzyme B on MHC class I tetramer-
stained EBV-specific CD8
+ T cells stimulated with their cognate
antigen. Being able to enumerate not only frequencies of
responses, but also proportions of functional cells among EBV-
specific CD8
+ T cells, we clearly establish that EBV-specific CD8
+
T cells are present at slightly elevated frequency but functionally
impaired in SLE patients. Indeed, EBV-specific T cells from SLE
patients exhibit a reduced capacity to secrete IFN-c, TNF-a, IL-2
and MIP-1b and an impaired cytotoxic granule exocytosis process.
The increased frequency of CD8
+ T cells specific for lytic EBV
antigens is most likely due to recurrent EBV replication. However,
the elevated frequency is counterbalanced by a global T cell
lymphopenia, which is a common clinical feature of SLE.[25]
Furthermore, functional impairment at the single-cell level
coincides with a diminished absolute number of functional EBV-
specific CD8
+ T cells in SLE patients. Interestingly, there was no
direct inverse correlation between EBV-specific cell function
(cytokine secretion and cytotoxicity) and EBV viral load (data not
shown). This is probably related to the fact that EBV viral loads
fluctuate relatively rapidly (Figure 5) and frequently enough to
have a long lasting imprint on T cell functions.
A link between CMV and SLE has also been debated due to the
fact that more frequent CMV seropositivity and elevated CMV
viral loads have been reported in SLE patients in a single
study.[26] SLE patients from the present study were also found
more frequently seropositive for CMV than healthy controls
(Table 1). However, CMV viral loads were not found elevated and
dysfunctional anti-CMV T cell responses were not observed in
SLE patients, compared to healthy controls. Altogether, the
immune alterations described in our study affect preferentially
EBV-specific responses and not responses to another herpesvirus,
CMV.
The impaired functional status of EBV-specific T cells in SLE
patients could be due to an alteration in their phenotype, possibly
caused by recurrent exposure to EBV antigens. We observed
(Figure S3 in Text S1) that proliferation marker Ki-67 and
activation markers CD69, HLA-DR and CD38 were up-regulated
on CD8
+ T cells from SLE patients as previously reported.
[20,27,28] Taken together, this demonstrates that T cell hyper
activation and hyper proliferation are essential factors in SLE
pathophysiology.
PD-1 has previously been associated with diminished functional
capacity [22] and up-regulation is commonly observed on
chronically stimulated antiviral T cells.[23,29] Of note, a single
nuclear polymorphism (SNP) within the gene encoding the PD-1
receptor has been identified as an inheritable risk factor of
SLE.[30] We therefore reasoned that the PD-1 receptor could be
involved in the EBV-related immune alterations observed in SLE
patients. As shown, compared to control lytic EBV-specific CD8
+
T cells, PD-1 surface expression levels are indeed up-regulated on
lytic EBV-specific CD8
+ T cells from SLE patients. The functional
relevance of this marker was corroborated by the fact that blocking
PD-1 signaling restores both lytic and latent EBV-specific CD8
+ T
cell function.
PD-1 expression is not only up-regulated on EBV-specific
CD8
+ T cells but also, most likely, on pathogenic T cells, since
elevated PD-1 levels are observed on the global CD8
+ Tc e l l
compartments (Figure S4B in Text S1). We also observed that not
only EBV-specific T cells show signs of impairment in SLE
patients as polyclonal stimulation reveal significantly diminished
cytokine responses in the global CD8
+ T cell compartment
(Figures S4C-E in Text S1). Therefore PD-1 up-regulation in
SLE patients might represent an important regulatory mecha-
nism, limiting the severity of pathogenic T cell responses. This
view is also supported by the fact that a recessive PD-1 knock-out
SNP is overrepresented in families of individuals suffering from
SLE,[30] suggesting a protective role for PD-1 regulation in SLE
immunopathogenesis.
It is still debated whether EBV reactivation is a cause or
consequence of SLE disease activity. We first noted that EBV
replication in our initial cross-sectional studies is usually
undetectable at time of hospital admission for SLE flare (5 out
of 7 cases). To address this issue more directly we longitudinally
followed patients starting at their first hospital visit after initiation
of disease flare until flare resolution. In this way we observed that
EBV replication is maximal post flare onset. The relatively narrow
window of EBV replication assessed through longitudinal analysis
suggests that cross-sectional studies most probably underestimate
the occurrence of EBV reactivation in active patients. This would
explain why no significant differences were recorded between
active and inactive patients in terms of EBV viral loads (Figure 1).
More longitudinal studies will be necessary to formally rule out the
implication of EBV in the triggering of SLE flares. In particular, it
would be interesting to monitor EBV not only at flare onset, but
also shortly before active disease. Nevertheless our results strongly
suggests that EBV replication is more likely a result of B cell
activation associated with active disease, rather than a triggering
factor for disease re-activation.
However, EBV can contribute to the vicious circle of
autoimmunity in several ways. As previously mentioned, EBV
can be responsible for the induction of cross-reactive B and T cell
responses.[15,16] Moreover, it was shown in healthy individuals
that EBV induces type 1 interferon (IFN) production by
plasmacytoid dendritic cells,[31] a subset of cytokines which are
central features of SLE active disease.[32] Thus, iterative episodes
of viral replication could account, at least in part, for the over-
expression of IFN and IFN-induced genes observed in
SLE.[33,34] The potential implications of EBV in SLE immuno-
pathology in relation to an impaired EBV-specific T cell response
suggest that pharmaceutical or immunological anti-EBV interven-
tions might potentially be beneficial to these patients.
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cell activation [35,36] induces an activation of the EBV lytic cycle
in infected B cells, which leads to a burst of EBV replication. In
response, EBV-specific T cells are activated in order to control
viral replication and may eventually cross-react with self antigens
and lead to auto-immune manifestations. EBV-induced IFN may
also take part in SLE immunopathology. Repetitive episodes of
viral replication ultimately results in PD-1 mediated impairment of
EBV-specific cytotoxic and cytokine-secreting T cells. This
impairment partially limits the risks of cross-reactive tissue injuries,
but at the same time explains why EBV replication is less
suppressed in SLE patients.
Association between SLE and EBV has been studied for 40
years, and EBV remains suspected to induce SLE early on in
life.[37,38] In established SLE disease, it is debated whether
autoimmunity is triggered by reactivation of pathogens, such as
EBV or vice versa.[2] In our study of adults with established disease,
frequent EBV reactivation appears to be an aggravating
consequence, rather than a cause, of SLE immunopathology.
Future studies are needed to elucidate whether EBV contributes to
the initiation of disease in young healthy individuals.
Materials and Methods
Ethics statement
All samples were obtained following acquisition of the study
participants’ and/or their legal guardians’ written informed
consent. The study protocol was reviewed and approved by the
local ethics committees (Comite ´ de Protection des Personnes Ile de
France VI).
Patients and healthy donors
We enrolled a total of 149 study subjects, including 118
consecutive SLE patients, defined according to the American
College of Rheumatology classification criteria,[39] as well as 31
healthy (H) control subjects. SLEDAI for individual SLE patients
was determined at the time of sample collection.[40] SLE patients
were subdivided in two groups consisting of 76 inactive
(SLEDAI,6) and 42 active (SLEDAI$6) SLE patients. Included
subjects were then selected according to their HLA genotype
(HLA-A*0201, A*1101, B*0702, B*0801), for which well charac-
terized EBV and CMV peptide antigens have been de-
scribed.[41,42,43,44]
EBV and CMV serology and quantification
The serological status of EBV and CMV were measured by
serum ELISA (BIO Advance, France) according to the manufac-
turer’s instructions. Both EBV and CMV DNA loads were
measured using in-house real-time PCR assays. EBV and CMV
PCRs were carried out on the same DNA extract obtained from
peripheral blood mononuclear cells (PBMCs) or total blood for
longitudinal studies, using the QIamp Blood DNA kit (Qiagen,
France) according to the manufacturer’s instructions. Real-time
quantitative PCRs based on hydrolysis probe technology were
carried out on a LightCycler 480 (Roche Diagnostics, France) as
previously described by Deback et al.[45] Real-time PCR accuracy
was previously confirmed by the Quality Control for Molecular
Diagnosis (QCMD) 2008 proficiency panel. The human albumin
gene was quantified in each DNA sample, to enable quantitation
of the copy number per million cells of EBV and CMV.
Antibodies and peptide/MHC tetramers
Directly conjugated and unconjugated antibodies were obtained
from the following providers: BD Biosciences (San Jose, CA): Ki-
67 [FITC], HLA-DR [PE–cyanin 7], CD38 [Alexa Fluor 700],
CTLA-4 [cyanin 5-PE], CD107a [cyanin 5–PE], Granzyme B
[A647], IFN-c [Alexa Fluor 700], IL-2 [APC] and TNF-a [PE–
cyanin 7]; R&D Systems (Abingdon, UK): MIP-1b [FITC], PD-1
[FITC]; Caltag (Burlingam, CA): CD8 [Alexa Fluor 405]; Dako
(Glostrup, Denmark): CD3 [cascade yellow] and BioLegend (San
Diego, CA): CD69 [APC-Cy7]. Peptide/MHC tetramers were
produced as previously described [41] and included the following
epitopes: HLA-A*0201 CMV pp65-NV9; HLA-A*0201 EBV
BMLF1-GL9 and BMRF1-YV9; HLA-A*1101 EBV EBNA-3B
IK9, EBNA-3B AK10; HLA-B*0702 CMV pp65-TM10; HLA-
B*0801 EBV BZLF1-RL8 and EBNA-3A-FL9.
Cytometry and polyfunctional analysis
PBMCs isolated on ficoll gradients (PAA, France) were stained
with titrated antibodies specific for cell surface markers, followed
by staining for intra-cellular Ki-67, according to manufacturer’s
recommendation.
For polyfunctional analysis, PBMCs were stimulated in the
presence of peptide antigen (5 mM) and PE-Cy5 conjugated anti-
CD107a antibody over night at 37uC in a 5% CO2 incubator.
Cytokine secretion was blocked by the addition of 2.5 mg/ml
monensin and 5 mg/ml Brefeldin A (Sigma-Aldrich, St. Louis,
MO). Cells were then stained with corresponding PE-conjugated
peptide MHC class I tetramer (0.5 mg per 10
6 cells) and directly
conjugated anti-CD3 and anti-CD8 antibodies. Cells were then
fixed and permeabilized with Cytofix/Cytoperm (BD Biosciences)
according to manufacturer’s instructions. Finally, cells were
stained with anti-cytokine antibodies and/or anti-granzyme B
antibody for 15 minutes at room temperature.
Samples were acquired on a BD LSRII flow cytometer (Becton
Dickinson) with appropriate isotype controls and color compen-
sation. Data were analysed with FACSDiva (BD Biosciences) and
FlowJo (TreeStar Inc) softwares. Unstimulated cells for each
sample, treated under the same experimental conditions served as
negative controls, and background values were subtracted from
the analysis of the stimulated samples.
Blockade of PD-1 signal pathway
PBMCs were cultured for 10 days at 37uC 5% C02, in RPMI
supplemented with 5% human serum and a cytokine cocktail mix
(20 ng/ml of IL-7 and 20 ng/ml IL-2 (R&D Systems, Minneap-
olis, MN)). Cells were stimulated with or without EBV or CMV
peptide (1 mg/ml) in the presence of either isotype control
antibodies or both anti-PD-L1 and anti-PD-L2 (10 mg/ml). On
day 10, cells were re-stimulated with peptide (1 mg/ml) overnight
and proliferation and functionality was assessed by cell counting
and flow cytometry. Antagonistic antibodies were kindly provided
by Pr. Gordon Freeman (Dana Farber Institute, Boston).
Data management and statistical analysis
Clinical information and flow cytometric analysis were gathered
in a database (Office Access 2003, Microsoft France, Issy-les-
Moulineaux, France).
Differences of continuous variables between patient groups were
tested using the Mann-Whitney U-test (unpaired) and the
Wilcoxon matched pairs test (paired). Differences of categorical
variables, such as sex and detectable viral load, between groups
were tested with Fisher’s exact test. All tests were 2-sided and a p
value ,0.05 was considered statistically significant. To exclude the
influence of treatment-related factors on EBV viral load and EBV
specific CD8
+ T cell cytokine secretion we built multivariate
regression models. In these models, EBV viral load and EBV
specific CD8
+ T cell cytokine secretion were used as dependent
Impaired T Cell Suppression of EBV in SLE
PLoS Pathogens | www.plospathogens.org 9 October 2011 | Volume 7 | Issue 10 | e1002328variables, and all treatment-related variables were included as
explanatory variables. Statistical analysis was performed using
GraphPad Prism Ver. 4.03 (GraphPad Software Inc), JMP7 (SAS
Software, NC, USA), Pestle Ver. 1.6.2 and Spice Ver. 4.2.3 (Mario
Roederer, ImmunoTechnology Section, VRC/NIAID/NIH) soft-
wares.[46]
Supporting Information
Text S1 Supplemental Materials and Methods and 4 supple-
mental figures.
(PDF)
Acknowledgments
We acknowledge Pr. Gordon Freeman and the Dana Farber Institute for
providing PD-L1 and PD-L2 blocking antibodies. We further acknowledge
Jørgen Larsen for Microsoft Access database support.
Author Contributions
Conceived and designed the experiments: ML DS ZA GG. Performed the
experiments: ML DS CD DB KD CP. Analyzed the data: ML DS.
Contributed reagents/materials/analysis tools: LP LA AM MM ZA. Wrote
the paper: ML DS LA VA ZA GG.
References
1. James JA, Harley JB, Scofield RH (2001) Role of viruses in systemic lupus
erythematosus and Sjogren syndrome. Curr Opin Rheumatol 13: 370–376.
2. Munz C, Lunemann JD, Getts MT, Miller SD (2009) Antiviral immune
responses: triggers of or triggered by autoimmunity? Nat Rev Immunol 9:
246–258.
3. Evans AS, Rothfield NF, Niederman JC (1971) Raised antibody titres to E.B.
virus in systemic lupus erythematosus. Lancet 1: 167–168.
4. Alspaugh MA, Henle G, Lennette ET, Henle W (1981) Elevated levels of
antibodies to Epstein-Barr virus antigens in sera and synovial fluids of patients
with rheumatoid arthritis. J Clin Invest 67: 1134–1140.
5. Barzilai O, Ram M, Shoenfeld Y (2007) Viral infection can induce the
production of autoantibodies. Curr Opin Rheumatol 19: 636–643.
6. Poole BD, Scofield RH, Harley JB, James JA (2006) Epstein-Barr virus and
molecular mimicry in systemic lupus erythematosus. Autoimmunity 39: 63–70.
7. Vaughan JH, Valbracht JR, Nguyen MD, Handley HH, Smith RS, et al. (1995)
Epstein-Barr virus-induced autoimmune responses. I. Immunoglobulin M
autoantibodies to proteins mimicking and not mimicking Epstein-Barr virus
nuclear antigen-1. J Clin Invest 95: 1306–1315.
8. Sabbatini A, Dolcher MP, Marchini B, Bombardieri S, Migliorini P (1993)
Mapping of epitopes on the SmD molecule: the use of multiple antigen peptides
to measure autoantibodies in systemic lupus erythematosus. J Rheumatol 20:
1679–1683.
9. Hjalgrim H, Askling J, Rostgaard K, Hamilton-Dutoit S, Frisch M, et al. (2003)
Characteristics of Hodgkin’s lymphoma after infectious mononucleosis.
N Engl J Med 349: 1324–1332.
10. Thacker EL, Mirzaei F, Ascherio A (2006) Infectious mononucleosis and risk for
multiple sclerosis: a meta-analysis. Ann Neurol 59: 499–503.
11. Gross AJ, Hochberg D, Rand WM, Thorley-Lawson DA (2005) EBV and
systemic lupus erythematosus: a new perspective. J Immunol 174: 6599–6607.
12. Kang I, Quan T, Nolasco H, Park SH, Hong MS, et al. (2004) Defective control
of latent Epstein-Barr virus infection in systemic lupus erythematosus. J Immunol
172: 1287–1294.
13. Moon UY, Park SJ, Oh ST, Kim WU, Park SH, et al. (2004) Patients with
systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load
in blood. Arthritis Res Ther 6: R295–302.
14. O’Reilly RJ, Small TN, Papadopoulos E, Lucas K, Lacerda J, et al. (1997)
Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphopro-
liferative disorders in recipients of marrow allografts. Immunol Rev 157:
195–216.
15. Wucherpfennig KW, Strominger JL (1995) Molecular mimicry in T cell-
mediated autoimmunity: viral peptides activate human T cell clones specific for
myelin basic protein. Cell 80: 695–705.
16. Lunemann JD, Jelcic I, Roberts S, Lutterotti A, Tackenberg B, et al. (2008)
EBNA1-specific T cells from patients with multiple sclerosis cross react with
myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med 205:
1763–1773.
17. McClain MT, Rapp EC, Harley JB, James JA (2003) Infectious mononucleosis
patients temporarily recognize a unique, cross-reactive epitope of Epstein-Barr
virus nuclear antigen-1. J Med Virol 70: 253–257.
18. Mascia MT, Sandri G, Guerzoni C, Roncaglia R, Mantovani G, et al. (2008)
Detection of autoimmunity in early primary Epstein-Barr virus infection by
Western blot analysis. Clin Exp Rheumatol 26: 1034–1039.
19. Tsokos GC, Magrath IT, Balow JE (1983) Epstein-Barr virus induces normal B
cell responses but defective suppressor T cell responses in patients with systemic
lupus erythematosus. J Immunol 131: 1797–1801.
20. Berner BR, Tary-Lehmann M, Yonkers NL, Askari AD, Lehmann PV, et al.
(2005) Phenotypic and functional analysis of EBV-specific memory CD8 cells in
SLE. Cell Immunol 235: 29–38.
21. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, et al. (2003)
Sensitive and viable identification of antigen-specific CD8+ T cells by a flow
cytometric assay for degranulation. J Immunol Methods 281: 65–78.
22. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, et al. (2006) PD-1
expression on HIV-specific T cells is associated with T-cell exhaustion and
disease progression. Nature 443: 350–354.
23. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, et al. (2006) Restoring
function in exhausted CD8 T cells during chronic viral infection. Nature 439:
682–687.
24. Posnett DN (2008) Herpesviruses and autoimmunity. Curr Opin Investig Drugs
9: 505–514.
25. Rivero SJ, Diaz-Jouanen E, Alarcon-Segovia D (1978) Lymphopenia in systemic
lupus erythematosus. Clinical, diagnostic, and prognostic significance. Arthritis
Rheum 21: 295–305.
26. Hrycek A, Kusmierz D, Mazurek U, Wilczok T (2005) Human cytomegalovirus
in patients with systemic lupus erythematosus. Autoimmunity 38: 487–491.
27. Jury EC, Flores-Borja F, Kalsi HS, Lazarus M, Isenberg DA, et al. (2010)
Abnormal CTLA-4 function in T cells from patients with systemic lupus
erythematosus. Eur J Immunol 40: 569–578.
28. Moulton VR, Tsokos GC (2010) Alternative splicing factor/ splicing factor 2
regulates the expression of the zeta subunit of the human T cell receptor-
associated CD3 complex. J Biol Chem 285: 12490–12496.
29. Sauce D, Almeida JR, Larsen M, Haro L, Autran B, et al. (2007) PD-1
expression on human CD8 T cells depends on both state of differentiation and
activation status. AIDS 21: 2005–2013.
30. Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, et al. (2002) A
regulatory polymorphism in PDCD1 is associated with susceptibility to systemic
lupus erythematosus in humans. Nat Genet 32: 666–669.
31. Quan TE, Roman RM, Rudenga BJ, Holers VM, Craft JE (2010) Epstein-Barr
virus promotes interferon-alpha production by plasmacytoid dendritic cells.
Arthritis Rheum 62: 1693–1701.
32. Banchereau J, Pascual V (2006) Type I interferon in systemic lupus
erythematosus and other autoimmune diseases. Immunity 25: 383–392.
33. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, et al. (2003) Interferon
and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med
197: 711–723.
34. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J (2001) Induction of
dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus.
Science 294: 1540–1543.
35. Jacobi AM, Reiter K, Mackay M, Aranow C, Hiepe F, et al. (2008) Activated
memory B cell subsets correlate with disease activity in systemic lupus
erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis
Rheum 58: 1762–1773.
36. Ten Boekel E, Siegert CE, Vrielink GJ, Van Dam VC, Ceelen A, et al. (2007)
Analyses of CD27++ plasma cells in peripheral blood from patients with
bacterial infections and patients with serum antinuclear antibodies. J Clin
Immunol 27: 467–476.
37. James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJ, et al. (1997)
An increased prevalence of Epstein-Barr virus infection in young patients
suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 100:
3019–3026.
38. McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, et al. (2005) Early
events in lupus humoral autoimmunity suggest initiation through molecular
mimicry. Nat Med 11: 85–89.
39. Hochberg MC (1997) Updating the American College of Rheumatology revised
criteria for the classification of systemic lupus erythematosus. Arthritis Rheum
40: 1725.
40. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992)
Derivation of the SLEDAI. A disease activity index for lupus patients. The
Committee on Prognosis Studies in SLE. Arthritis Rheum 35: 630–640.
41. Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB (2002) Epitope-
specific evolution of human CD8(+) T cell responses from primary to persistent
phases of Epstein-Barr virus infection. J Exp Med 195: 893–905.
42. Sauce D, Larsen M, Curnow SJ, Leese AM, Moss PA, et al. (2006) EBV-
associated mononucleosis leads to long-term global deficit in T-cell responsive-
ness to IL-15. Blood 108: 11–18.
43. Scotet E, David-Ameline J, Peyrat MA, Moreau-Aubry A, Pinczon D, et al.
(1996) T cell response to Epstein-Barr virus transactivators in chronic
rheumatoid arthritis. J Exp Med 184: 1791–1800.
44. Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, et al. (1996) The
human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated
Impaired T Cell Suppression of EBV in SLE
PLoS Pathogens | www.plospathogens.org 10 October 2011 | Volume 7 | Issue 10 | e1002328by structural protein pp65: frequency, specificity, and T-cell receptor usage of
pp65-specific CTL. J Virol 70: 7569–7579.
45. Deback C, Geli J, Ait-Arkoub Z, Angleraud F, Gautheret-Dejean A, et al. (2009)
Use of the Roche LightCycler 480 system in a routine laboratory setting for
molecular diagnosis of opportunistic viral infections: Evaluation on whole blood
specimens and proficiency panels. J Virol Methods 159: 291–294.
46. Roederer M, Nozzi JL, Nason MC (2011) SPICE: exploration and analysis of
post-cytometric complex multivariate datasets. Cytometry A 79: 167–174.
Impaired T Cell Suppression of EBV in SLE
PLoS Pathogens | www.plospathogens.org 11 October 2011 | Volume 7 | Issue 10 | e1002328